AYTU BIOPHARMA INC
AYTUNASDAQTrading Snapshot
- Day Range
- $2.65 β $2.66
- 52-Week Range
- $1.75 β $3.07
- Volume (shares)
- 148,610
- Avg Volume (shares)
- β
- Shares Outstanding
- 10.9M
- Next Earnings
- 2027-02-02
Fundamentals Snapshot
- Annual Revenue
- $58M
- Last Q Revenue
- $16M
- P/E Ratio
- β
- P/S Ratio
- 0.5x
- EPS (TTM)
- $-1.49
- Dividend Yield
- β
- Dilution (1yr)
- +22.7%
AYTU BIOPHARMA INC
AYTUAbout AYTU BIOPHARMA INC
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

STOCK ALERT - The M&A Class Action Firm Is Investigating the Merger β AYTU, ADT, CCC and CBNK β IS IT A FAIR DEAL FOR YOU?
NEW YORK, Nov. 22, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the βM&A Class Action Firmβ), has recovered millions of dollars for shareholders and is recognized as a T

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aytu BioPharma, Inc. (NASDAQ: AYTU)
NEW YORK, Nov. 18, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC Β (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top

Are GLND, RPID, AYTU Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Aytu BioPharma, Inc. (Nasdaq β AYTU), Rapid Micro Biosystems, Inc. (Nasdaq β RPID), Advantage Energy Ltd. (OTC β AAVVF), Canaccord Genuity Group Inc. (OTC β CCORF)
BALA CYNWYD, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith

AYTU Shareholder Alert: Ademi LLP Investigates Whether Buyout Fairly Values Aytu Biopharma, Inc.
AYTU shareholders will receive just $2.70 per share in a tender offer transaction; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers CLICK HERE TO JOIN MILWAUKE

Why Aytu Biopharma Shares Are Trading Higher By 43%; Here Are 20 Stocks Moving Premarket
Shares of Aytu Biopharma Inc (NASDAQ:AYTU) rose sharply in pre-market trading after the pharmaceutical company reported its fiscal 2027 first-quarter results and announced a proposed acquisition by Rosemont Pharmaceutica